• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Dyadic International Inc.

    8/19/25 6:45:08 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    DYADIC INTERNATIONAL INC

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    26745T101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    26745T101


    1Names of Reporting Persons

    Bandera Partners LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,383,308.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,383,308.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,383,308.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.6 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    26745T101


    1Names of Reporting Persons

    Bylinsky Gregory
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,383,308.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,383,308.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,383,308.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.6 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    26745T101


    1Names of Reporting Persons

    Gramm Jefferson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,383,308.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,383,308.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,383,308.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.6 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    DYADIC INTERNATIONAL INC
    (b)Address of issuer's principal executive offices:

    Item 2. 
    (a)Name of person filing:

    This statement is filed by Bandera Partners LLC, a Delaware limited liability company ("Bandera Partners"), Gregory Bylinsky and Jefferson Gramm. Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Bandera Partners, Mr. Bylinsky and Mr. Gramm are filing this Statement with respect to 1,383,308 shares of Common Stock, par value $0.001 per share, of the Issuer (the "Shares") directly held by Bandera Master Fund L.P., a Cayman Islands exempted limited partnership ("Bandera Master Fund"). Bandera Partners is the investment manager of Bandera Master Fund and may be deemed to have beneficial ownership over the Shares held by Bandera Master Fund by virtue of the sole and exclusive authority granted to Bandera Partners by Bandera Master Fund to vote and dispose of such Shares. Messrs. Bylinsky and Gramm are Managing Members of Bandera Partners and may be deemed to beneficially own the Shares held by Bandera Master Fund. The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that he or it does not directly own. Without limiting the foregoing sentence, Bandera Master Fund specifically disclaims beneficial ownership of the Master Fund's Shares by virtue of its inability to vote or dispose of such Shares.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is 138 Atlantic Avenue, Brooklyn, NY 11201.
    (c)Citizenship:

    Bandera Partners is organized under the laws of the State of Delaware. Each of Messrs. Bylinsky and Gramm is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    26745T101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    All ownership information reported in this Item 4 is as of the close of business on June 30, 2025. Bandera Partners LLC 1,383,308 Shares Gregory Bylinsky 1,383,308 Shares Jefferson Gramm 1,383,308 Shares
    (b)Percent of class:

    Bandera Partners LLC 4.6% (based on 30,090,661 Shares outstanding as of May 13, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 14, 2025) Gregory Bylinsky 4.6% (based on 30,090,661 Shares outstanding as of May 13, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 14, 2025) Jefferson Gramm 4.6% (based on 30,090,661 Shares outstanding as of May 13, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 14, 2025)
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons on February 14, 2022.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Bandera Partners LLC
     
    Signature:/s/ Gregory Bylinsky
    Name/Title:Gregory Bylinsky, Managing Member
    Date:08/19/2025
     
    Bylinsky Gregory
     
    Signature:/s/ Gregory Bylinsky
    Name/Title:Gregory Bylinsky
    Date:08/19/2025
     
    Gramm Jefferson
     
    Signature:/s/ Jefferson Gramm
    Name/Title:Jefferson Gramm
    Date:08/19/2025
    Get the next $DYAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

    Completed Strategic Leadership and Operational Transformation from R&D to Commercial OperationsRebranded as Dyadic Applied BioSolutions to Reflect Our New Operational PrioritiesFull Redesign of Corporate Website to Prioritize Commercial Execution and Long-term Value CreationCompleted $5.3 million Equity Offering to Strengthen Liquidity and Help Fund Pipeline and Commercial GrowthAchieved Key Development and Commercial Milestones in Life Sciences and Nutrition MarketsAdvanced Multiple Recombinant Protein Programs Toward CommercializationCash, Cash Equivalents, Restricted Cash and Cash Equivalent, and Investment Grade Securities of $7.3 million as of June 30, 2025; Additional $5.3 million of N

    8/13/25 4:01:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

    JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025. Conference Call Information Date: Wednesday, August 13, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-

    8/5/25 4:11:35 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

    JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share. The Company expects the gross proceeds from this offering to be approximately $5.75 million, before deducting the underwriting discount and ot

    7/31/25 8:47:58 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Hazelton Joseph P bought $24,700 worth of shares (26,000 units at $0.95), increasing direct ownership by 20% to 155,340 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    8/5/25 5:00:10 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tarnok Michael P. converted options into 10,776 shares, increasing direct ownership by 4% to 281,033 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    6/24/25 10:34:28 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bose Arindam converted options into 10,776 shares, increasing direct ownership by 21% to 61,535 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    6/24/25 10:34:02 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Dyadic International Inc.

    SCHEDULE 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    8/19/25 6:45:08 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    8/13/25 4:17:38 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Dyadic International Inc.

    10-Q - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    8/13/25 4:16:36 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dyadic International downgraded by Dawson James

    Dawson James downgraded Dyadic International from Buy to Neutral

    7/18/22 9:59:51 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. initiated coverage on Dyadic International with a new price target

    HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00

    12/17/21 6:17:22 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Hazelton Joseph P bought $24,700 worth of shares (26,000 units at $0.95), increasing direct ownership by 20% to 155,340 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    8/5/25 5:00:10 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Leadership Updates

    Live Leadership Updates

    View All

    Dyadic Appoints Doug Pace to Its Executive Leadership Team

    JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

    10/9/23 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Appoints Chief Business Officer to Executive Leadership Team

    JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

    11/9/21 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Financials

    Live finance-specific insights

    View All

    Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

    JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025. Conference Call Information Date: Wednesday, August 13, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-

    8/5/25 4:11:35 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

    Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest

    5/14/25 4:05:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

    JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

    5/1/25 3:00:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/13/24 4:41:59 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/1/24 4:15:18 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    3/14/23 4:01:06 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care